Lazard Transactions


DISCLAIMER: Transaction value is approximate and is based on information disclosed by the parties to the transaction or other public sources. In addition, in the case of transactions consummated in currencies other than U.S. dollars, Lazard has converted the value using the exchange rate published on the date of announcement. Lazard makes no representation or warranty with respect to the accuracy or completeness of the value provided

Clear all Clear

Download results

Showing 1 to 10 of 4012 Results

June 01, 2026
France, United States

Servier to Acquire Edgewise Therapeutics’ Muscular Dystrophy Business

$2.6 Billion

June 01, 2026
France, United Kingdom, United States, Jersey

Waldencast Announces Sale of Obagi Medical to Bridgepoint

$460 Million

May 29, 2026
Lithuania, Latvia, United States

Bite Group agrees to sell and lease back its towers infrastructure in Lithuania and Latvia

$563.4 Million

May 29, 2026
United Kingdom

NCC Group announces the sale of its Escode business to TDR Capital LLP, creating a pure-play global Cyber security and resilience business

$368.7 Million

May 26, 2026
United States

Vaccine Company to be acquired by Lilly to advance best-in-class vaccine candidates for Epstein-Barr Virus and other infectious diseases

$1.5 Billion

May 25, 2026
Brazil, France

Frances Loxam to buy controlling stake in Brazils Mills

$1 Billion

May 21, 2026
United Kingdom, United States

Sun Communities, Inc. Announces Agreement To Sell UK Assets For Approximately $1.03 Billion In An All-Cash Transaction

$1 Billion

May 21, 2026
France

Lazard acted as exclusive financial advisor to Kayrros on the sale of its defence activities to Safran.AI

Undisclosed

May 21, 2026
France, United Kingdom

Energy Aspects agrees to acquire Kayrros

Undisclosed

May 19, 2026
United States

Lilly to Acquire Orna Therapeutics to Advance Cell Therapies

$2.4 Billion